Scinai Immunotherapeutics Announces $4.0 Million Financing Through a Private Placement and Warrant Inducement
Key Highlights
- ➤Scinai (SCNI) expects approximately $4.0 million in gross financing proceeds
- ➤Private placement includes 2,458,334 ADSs and warrants for 3,687,501 ADSs
- ➤Existing warrants for 879,194 ADSs will be exercised immediately at $1.20
- ➤New warrants cover 1,318,791 ADSs, exercisable at $1.20 for five years
- ➤Proceeds will expand CDMO operations, advance customer programs, and fund immunotherapy investments
Scinai Immunotherapeutics Announces $4.0 Million Financing Through a Private Placement and Warrant Inducement PR Newswire
JERUSALEM, October 14, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company operating a growing contract development and manufacturing organization ("CDMO") alongside an immunology-focused therapeutic development platform, today announced that it has entered into a securities purchase agreement with an existing life sciences institutional investor for the purchase and sale of 2,458,334 American Depositary Shares ("ADSs") (or pre-funded warrants in lieu thereof), each ADS representing 40,000 ordinary shares, together with Series A-1 warrants to purchase up to 3,687,501 ADSs, at an exercise price of $1.20 per ADS, exercisable immediately with a term of five years, at a combined purchase price of $1.20 per ADS and accompanying warrants (or $1.1999 per pre-funded warrant and accompanying warrants). Each pre-funded warrant will have a remaining exercise price of $0.0001 per ADS.
Get started
Create a free account to read the full story.